Navigation Links
ChemDiv and Achaogen Enter Into a Discovery Collaboration
Date:1/29/2008

SAN DIEGO, Jan. 29 /PRNewswire/ -- ChemDiv, Inc., a leading chemistry-driven global contract research organization, has announced today that it has entered into a discovery collaboration with Achaogen, Inc., South San Francisco, CA. Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds. Financial terms of the collaboration were not disclosed.

"We look forward to collaborating with Achaogen on this exciting project where ChemDiv's strong medicinal chemistry expertise and integrated drug discovery capabilities will provide our partner with the tools for successful research operations and help them achieve rapid progress in this area," said Alex Khvat, Sr. Director of Chemistry at ChemDiv, Inc.

"We are pleased to be working with ChemDiv on this important medicinal chemistry effort to optimize SOS pathway inhibitors discovered by Achaogen," said Dr. Heinz Moser, Achaogen's Senior Vice President for Chemistry. "These inhibitors could prove to be powerful new tools in the battle against antimicrobial resistance."

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global chemistry-driven contract research organization delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. http://www.chemdiv.com

About Achaogen, Inc.:

Achaogen (a-KAY-oh-jen) is addressing the widespread emergence of bacterial resistance through the discovery and development of small molecule anti-infectives. Achaogen focuses on both known classes of antibiotics, as well as wholly novel classes of new drugs that will act through validated but as yet unexploited bacterial targets. For more information about Achaogen please contact John Hollway, Vice President, Business Development at 650-266-1120 or bd@achaogen.com, or visit http://www.achaogen.com.


'/>"/>
SOURCE ChemDiv, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
4. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
5. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
6. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
7. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
8. Neogen Acquires Kane Enterprises
9. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
10. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
11. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... ... June 14, 2017 , ... Slone Partners welcomed ... steered by the executive search firm, “Building Value in Precision Medicine: Can We ... of Foundation Medicine, led an open discussion with expert panelists Troy Cox, CEO ...
(Date:6/14/2017)... (PRWEB) , ... June 14, 2017 , ... The newest ... discover new therapeutic antibodies using rabbits that express human genes. ATGC, a spin out ... , Founded in 2015, ATGC is a translational genomics company. Its founders are ...
(Date:6/13/2017)... ... 2017 , ... Three newly formed companies have received $50,000 ... Recensa Therapeutics and Regennera, all P1V participants, will apply the funds to a ... a startup accelerator that helps launch and grow companies that have specific technology ...
(Date:6/13/2017)... ... 2017 , ... Presented at American Diabetes Association: Abstract #2017-LB-7091-Diabetes, ... to develop chronic kidney disease within four years , Study is the ... patients over a four year period , Results presented at the American ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):